Mountain View, Kalifornien (ots/PRNewswire) – Turn Biotechnologies, a developer of novel mRNA medicines and technologies, today announced the expansion of its eTurna™ delivery platform designed to overcome the biggest challenge for breakthrough therapies: safely and efficiently targeting specific organs and cells.
- Company announces development of novel ionizable lipids and stabilizing components
- The eTurna™ delivery platform is designed to improve safety and reduce immunogenicity
- The customizable platform can be optimized to treat a variety of cells, tissues and organs
- The platform can be used for different administration routes and loads
The significant expansion allows infinite customization possibilities for nucleic acid and can be optimized for other substances and different routes of administration to reach specific organs, tissues and cells.
The proprietary ionizable lipids used in the eTurna™ delivery platform are safer because they are biodegradable, non-toxic, and exit the body more quickly while providing higher encapsulation capacity and charge. Because the platform can use PEG-free stabilizing components, the delivery system minimizes or eliminates the immunogenicity associated with the PEG lipids currently used in LNPs. The platform’s optimized particle size also means higher transfection rates for the therapies it delivers.
“Our eTurna™ platform provides a solution to the biggest problem facing therapy developers worldwide: finding the optimal vehicle to deliver their breakthrough therapies to target tissues precisely and at the ideal dosage – safely “, says Anja Krammer, Managing Director of Turn Bio. “It is intended to enable the administration of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.”
“We are developing this breakthrough delivery platform to bring our therapies to the clinic, but eTurna also holds promise for other researchers developing other treatments,” she said.
Turn Bio’s initial drug candidates focus on treating the skin by targeting specific cells such as fibroblasts, endothelial cells and keratinocytes. The eTurna delivery platform has also proven effective in delivering mRNA into blood cells such as T cells and macrophages and shows promise in delivering therapies to virtually any organ, tissue or cell, with a Series of formulations.
INFORMATION ABOUT TURN BIOTECHNOLOGIES
Turn Bio is a preclinical-stage company focused on repairing tissue at the cellular level and developing novel drug delivery systems. Proprietary mRNA-based ERA™ reprogramming technology restores optimal gene expression by combating the effects of aging in the epigenome. This restores the cells’ ability to prevent or treat disease and heal or regenerate tissues. This will help fight incurable chronic diseases. The eTurna™ platform uses unique formulations to precisely target specific organs, tissues and cell types.
The company is completing preclinical research on tailored therapies for indications in dermatology and immunology and is developing therapies for ophthalmology, osteoarthritis and muscle. For more information, see www.turn.bio.
Questions & Contact:
Contact:
Jim Martinez, rightstorygroup
jim@rightstorygroup.com or (312) 543-9026
Photo – https://mma.prnewswire.com/media/2309236/eTurna_delivery_platform_fig_1.jpg
Photo – https://mma.prnewswire.com/media/2309237/eTurna_delivery_platform_fig_2.jpg
View original content:https://www.prnewswire.com/news-releases/turn-biotechnologies-extended-delivery-platform-eturna-to-solve-delivery-and-alignment-problems-challenging-the-industry-302025175 .html